Abstract
Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known to be modulated during the infection process, either by a pathogen or by a host. Recently there have been attempts to take advantage of this feature and design therapeutic inhibitors of DUBs that can be used to limit the spread of infection. This review is focused on exploring the potential of DUBs in the treatment of infectious diseases.
Keywords: Deubiquitinating enzymes, drug discovery, ubiquitin, infectious diseases, post-translational modifications.
Current Pharmaceutical Design
Title:Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases
Volume: 19 Issue: 18
Author(s): Bindu Nanduri, Akamol E. Suvarnapunya, Malabi Venkatesan and Mariola J. Edelmann
Affiliation:
Keywords: Deubiquitinating enzymes, drug discovery, ubiquitin, infectious diseases, post-translational modifications.
Abstract: Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known to be modulated during the infection process, either by a pathogen or by a host. Recently there have been attempts to take advantage of this feature and design therapeutic inhibitors of DUBs that can be used to limit the spread of infection. This review is focused on exploring the potential of DUBs in the treatment of infectious diseases.
Export Options
About this article
Cite this article as:
Nanduri Bindu, Suvarnapunya Akamol E., Venkatesan Malabi and Edelmann Mariola J., Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/1381612811319180008
DOI https://dx.doi.org/10.2174/1381612811319180008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Cellular Uptake Pathways of Nanoparticles: Process of Endocytosis and Factors Affecting their Fate
Current Pharmaceutical Biotechnology Combined Angiogenic and Osteogenic Factor Delivery for Bone Regenerative Engineering
Current Pharmaceutical Design CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Experimental Onco-Immunology Revisited
Current Cancer Therapy Reviews Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets β-estradiol Induces Mitochondrial Apoptosis in Cervical Cancer through the Suppression of AKT/NF-κB Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Advances in the Development of Virus-Like Particles as Tools in Medicine and Nanoscience
Current Chemical Biology Oxidative stress in carcinogenesis: new synthetic compounds with dual effects upon free radicals and cancer.
Current Medicinal Chemistry Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery LPS/TLR4 Pathways in Breast Cancer: Insights into Cell Signalling
Current Medicinal Chemistry Diagnostic Accuracy of Ultrasound for the Evaluation of Lateral Compartment Lymph Nodes in Papillary Thyroid Carcinoma
Current Medical Imaging The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation The Present and Future of Cervical Cancer Screening Programmes in Europe
Current Pharmaceutical Design Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry